FERAHEME Q Code: Q0139

Drug & Product Overview

HCPCS Descriptor Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)

HCPCS Added Date January 1, 2010

Manufacturer Multiple Manufacturers

Route of Administration Intravenous

Generic Status Multi-Source; Generic

Dosage Type Single-Dose

Dosage Form Injection

About FERAHEME

Feraheme is a medication aligned to the HCPCS Q Code: Q0139 for billing, pricing, and reimbursement purposes in the United States. Classified under Anti-Anemia, it is administered via the intravenous route and manufactured by multiple companies.

According to CMS Drug Use Information: This medication is used to treat "iron-poor" blood (iron deficiency anemia). Ferumoxytol is a form of injectable iron that is used if you cannot take iron by mouth because of side effects or an unsuccessful response to treatment. It is also used by people who have anemia due to long-term kidney disease. Iron is an important part of your red blood cells and is needed to carry oxygen throughout the body. Many people with kidney disease cannot get enough iron from food and require injections. People with kidney disease may also need extra iron because of blood loss during kidney dialysis treatment.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
00781-3154-01	Ferumoxytol	Sandoz Inc	510	510 MG / 17 ML
59338-0775-01	Feraheme	AMAG Pharmaceuticals, Inc	510	510 MG / 17 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

FERAHEME Pricing & Reimbursement

Q0139 Private Payer Reimbursement

$0.67 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

FERAHEME Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 13.86%

Avg. Days to File 21.0days

Avg. Days to Pay 45.9days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q0139 claims analytics on FocalPoint →

FERAHEME CPT Administration Codes

CPT Code	Description
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
96374 Login for More	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug), IV push, single, or initial substance/drug Login for More
96375 Login for More	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug. Login for More

Not on the CMS JW / JZ list

CMS does not include Feraheme (Q0139) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q0139. Wastage billing guide →

FERAHEME Medically Unlikely Edits (MUE)

The most billing units of Q0139 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

510 units / day

= 510 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

FERAHEME Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Iron Deficiency Anemia Iron deficiency anemia (IDA)

Drug Class

Iron [CS]Parenteral Iron Replacement [EPC]

Frequently Asked Questions

Is there an available Feraheme billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for FERAHEME.

Are there any available Feraheme patient assistance programs?

Our team has not identified a manufacturer-published source of patient assistance information for FERAHEME.

Where can I find Feraheme prescribing information?

FERAHEME prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date. Visit Here →

Where can I find Feraheme side effect information?

Our team has not yet identified a source of side effects information for FERAHEME. Please check back in a few weeks.

Does billing FERAHEME require JZ/JW wastage modifiers?

CMS does not include FERAHEME (Q0139) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q0139. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.